Alnylam Pharmaceuticals | ALNY - Trade Debtors


Alnylam Pharmaceuticals reported $883.96M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amgen USD 9.14B 432M Mar/2026
Arrowhead Research USD 15.68M 203.19M Mar/2026
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Moderna USD 71M 113M Mar/2026
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 482M 85M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Takeda JPY 876.35B 118.43B Mar/2026
Tectonic Therapeutic USD 0 270K Dec/2023
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026
Xencor USD 12M 17.3M Mar/2026